Background. Several uncontrolled observational studies have suggested that the tetracycline class of antibiotics may not be effective in treating Mycoplasma genitalium infection. The present study compared the efficacy of 1 g of azithromycin given as a single dose with that of 100 mg of doxycycline given twice a day for 7 days in eliminating M. genitalium infection.
Mycoplasma genitalium was first isolated from the urethra of 2 men with nongonococcal urethritis (NGU) in 1980 [1] and since then has been detected significantly more often in patients with acute NGU than in subjects without urethritis, independent of the presence of Chlamydia trachomatis [2] . The prevalence of M. genitalium in men with nonchlamydial NGU ranges from 18% to 46% [2] . In addition, the persistence of M. genitalium after antimicrobial therapy has been associated with the persistence or recurrence of NGU in a few studies [3, 4] . Administration of 100 mg of doxycycline orally twice a day for 7 days and of 1 g of azithromycin as a single dose are the standard of care for the treatment of NGU in men in the United States and are the current treatments administered in most publicly funded sexually transmitted disease clinics across the nation as well as in many other parts of the world [5] . Initially, in vitro studies suggested that M. genitalium was susceptible to tetracycline antibiotics as well as macrolides [6, 7] . However, a more recent study using real-time polymerase chain reaction (PCR) to measure multiplication of the organism indicated that resistance to tetracyclines can be detected in vitro [8] . More importantly, there is increasing clinical evidence from several small or uncontrolled observational studies indicating that the tetracycline class of antibiotics may be associated with high M. genitalium bacteriologic failure rates [4, 9, 10] .
The objective of the present study was to compare the efficacy of 1 g of azithromycin given as a single dose with that of 100 mg of doxycycline given twice a day for 7 days in eliminating M. genitalium infection and preventing recurrent clinical disease in men with M. genitalium-positive urethritis. A randomized design was used. The protocol was reviewed and approved by the Institutional Review Board of the Louisiana State University School of Medicine at New Orleans.
METHODS

From February 2002 through April 2004
, men presenting to the Delgado sexually transmitted disease clinic in New Orleans, Louisiana, with symptoms (discharge, dysuria, or penile irritation) or signs (urethral discharge) of urethritis and who had у5 polymorphonuclear leukocytes (PMNLs) per oil-immersion microscopic field in the urethral smear in the absence organisms typical of Neiserria gonorrhoeae were invited to participate by the study clinician. Exclusion criteria included receipt of antibiotic treatment within the last 30 days, history of allergy to the tetracycline or macrolide classes of antibiotics, unwillingness to return for follow-up visits, and unwillingness to avoid unprotected sexual intercourse. Participants who provided written informed consent were enrolled in the study.
Demographic data, clinical data, and data on sexually transmitted disease risk factors were recorded on a standardized questionnaire. A thin-wire Dacron-tipped swab was inserted 1-2 cm into the urethra and rotated several times to obtain a specimen for the M. genitalium PCR assay. This swab was placed in a dry tube and stored at 4ЊC. Each participant then provided ∼30 mL of first-voided urine, which was also stored at 4ЊC until the specimens were transported to the laboratory at the end of each day.
On arrival in the laboratory, the urethral swab specimen was frozen at Ϫ20ЊC until processing for the PCR assay. Five 1-mL aliquots of the urine specimen were frozen at Ϫ80ЊC, pending processing of one of the aliquots for the M. genitalium PCR assay. A pouch of ProbeTec urine preservative (Becton Dickinson) was then added to the remaining urine sample. This was stored for up to 3 days at 4ЊC before processing. Specific nucleic acid amplification assays were done weekly. The urine specimen was used for C. trachomatis and N. gonorrhoeae testing by the ProbeTec DNA amplification assay (Becton Dickinson), in accordance with the instructions on the package insert. The M. genitalium PCR assay was performed on the urine and swab specimens as described by Mena et al. [11] , although here amplicons were detected by dot blot rather than Southern blot analysis. Details of the methods for the dot blot assay are available on request.
By means of a computer-generated list, participants were randomized to receive either 100 mg of doxycycline orally twice a day for 7 days or 1 g of azithromycin orally as a single dose. The first dose of doxycycline and the 1-g dose of azithromycin were administered in the clinic. All participants were counseled about condom use, were asked to abstain from sexual intercourse until the first follow-up visit, and received recommendations for partner treatment in accordance with standard clinic protocol.
Patients were asked to return 10-17 days after enrollment. Those who returned were questioned about the resolution of symptoms, compliance with the doxycycline regimen, resumption of sexual activity, and use of condoms. The results of enrollment M. genitalium testing usually were not available at the time of the first follow-up visit. Men were told that they would be contacted by phone and/or letter if they were M. genitalium positive, to arrange for a second follow-up visit 31-41 days after enrollment. Also, all men who returned for the first follow-up visit were encouraged to return at any time if symptoms developed. The procedures for all follow-up visits were as described for the enrollment visit, except that testing for C. trachomatis and N. gonorrhoeae was not done for asymptomatic men. For purposes of analysis, all men who returned for the first time between 9 and 21 days after enrollment were considered to have returned for an early initial follow-up visit.
Men were considered to be positive for M. genitalium if either the urethral or the urine specimen tested positive for M. genitalium. Clinical failure was defined as the presence of symptoms of urethritis and/or discharge on examination plus у5 PMNLs per oil-immersion microscopic field in the urethral smear. Men deemed to have experienced clinical failure were treated with 500 mg of oral azithromycin on the first day followed by 250 mg daily for 4 subsequent days. These men were invited to return for a test-of-cure visit. Statistical comparisons were done using the x 2 test, Fisher's exact test, or Student's t test as appropriate for the data to be analyzed. Differences with were considered statistically significant. P ! .05
RESULTS
Of 398 men enrolled, 197 were randomized to receive azithromycin, and 201 were randomized to receive doxycycline. M. genitalium was detected in 78 participants (20%) (figure 1). There were 36 M. genitalium-infected men in the azithromycin group (18%) and 42 in the doxycycline group (21%). Demographic, behavioral, and clinical characteristics of the study population are summarized in table 1. There were no statistically significant differences between the 2 treatment groups for any analyzed variable.
Of the 42 doxycycline-treated men, 33 (79%) returned for least 1 follow-up visit, as did 26 (72%) of the 36 azithromycintreated men. Thirty-one of the doxycycline-treated men and 23 of the azithromycin-treated men were seen between 9 and 21 days after enrollment. The median interval between visits was 11 days for both treatment groups. Data on these men are summarized in table 2. Seventeen (55%; 95% confidence interval, 36%-72%) of the doxycycline-treated men were still positive for M. genitalium, compared with 3 (13%; 95% confidence interval, 3%-35%) of the azithromycin-treated men ( , 2-tailed Fisher's exact test). In the doxycycline P p .002 group, 14 (82%) of the persistently infected men had no symptoms or signs of urethritis and had !5 PMNLs per oil-immersion microscopic field in their urethral smears. This was also true for one of the persistently infected azithromycintreated men. There was only 1 symptomatic treatment failure at this visit, and that occurred in an azithromycin-treated man. All the doxycycline-treated men stated at the first follow-up visit that they had taken all or most of their medication. Only 2 men indicated that they had possibly been reexposed via a previous partner, and both of them were in the azithromycin group.
A total of 5 men returned for an initial follow-up visit 121 days after enrollment. The 2 in the doxycycline group returned 22 and 40 days after enrollment, and both experienced bacteriologic and clinical failure. The 3 men in the azithromycin group returned 23, 33, and 41 days after enrollment. All were M. genitalium negative, and only 1 complained of symptoms, although he did not have urethral inflammation.
A total of 27 men who were seen at an early initial followup visit returned for a second visit; 17 were in the doxycycline group, and 10 were in the azithromycin group. As summarized in table 3, 8 of 11 infected men in the doxycycline group experienced clinical failure, as did both of the infected men in the azithromycin group. An important observation is that, of these 10 clinical recurrences, 7 occurred in men who were infected with M. genitalium but were clinically cured at their initial follow-up visit. These 7 clinical relapses occurred between 20 and 28 days after enrollment. Two of the clinical recurrences occurred in men who were M. genitalium negative at the early initial follow-up visit, had resumed normal sexual activity, and may have been reinfected, although the possibility that the organism burden had been suppressed to below the level of detection at the first follow-up visit and that regrowth subsequently occurred cannot be ruled out.
The tenth patient who experienced clinical failure at the second follow-up visit had complained of mild dysuria at his initial follow-up visit, but he did not have urethral inflammation and thus was not classified as having experienced clinical failure and was not treated. He developed urethral discharge and had evidence of inflammation at the second visit 34 days after enrollment. Including the 1 patient with clinical failure at an initial follow-up visit р21 days after enrollment and the 2 men who returned for an initial visit 121 days after enrollment, 13 clinical failures occurred in the study overall. Ten (24%) of these occurred among the 42 doxycycline-treated men, compared with 3 (8%) among the 36 azithromycin-treated men ( , 2-tailed Fisher's exact test). Although the numbers P p .08 were too small for statistical analyses, there did not appear to be a difference between the 2 treatment groups in the time intervals from enrollment to the visit at which a clinical failure was identified.
Five men experiencing treatment failure who we had treated with the 5-day course of azithromycin returned for a third evaluation. Two of them had persistent M. genitalium infection; 1 had persistent symptoms and discharge on examination, and 1 was asymptomatic. These men were treated again with the 5-day course of azithromycin and then were lost to follow-up.
DISCUSSION
The present study is the first randomized-treatment trial to be conducted among M. genitalium-positive men presenting with urethritis. The results show that the rate of bacteriologic failure after doxycycline treatment is high. Of men who were retested between 9 and 21 days after enrollment, 55% were still infected with M. genitalium. Only 13% of men treated with a single 1-g dose of azithromycin were persistently infected at this followup visit ( ). All but 2 azithromycin-treated men denied P p .002 having unprotected sexual exposure during this interval, and all stated that they had complied with treatment; thus, these most likely represent treatment failures. These data support previously published findings from nonrandomized observational studies, which have shown similar high rates of treatment failure or recurrence among men treated with antibiotics belonging to the tetracycline class [4, 9, 10] .
In 1993, Horner et al. [12] first reported using an M. genitalium PCR assay to assess the results of treating M. genitaliumpositive urethritis with doxycycline. Four (29%) of 14 patients were persistently positive after treatment. Falk et al. [4] and Johannisson et al. [9] reported bacteriologic failure or reinfection rates of 63% and 62%, respectively, among small numbers of M. genitalium-infected Scandinavian men. More recently, Björnelius et al. [10] observed a failure or reinfection rate of 83% after a 9-day course of doxycycline among 76 men, the largest number studied to date. Our study is the first to perform test-of-cure evaluations among men shortly after completion of treatment. Fifty-five percent of men experienced failure of doxycycline treatment, suggesting that most of the posttreatment infections identified in the earlier studies were also due to treatment failure. In the present study, in which we documented M. genitalium eradication at the initial follow-up visit, we observed only 2 men who were likely to have been reinfected. Regardless of the mechanism of persistent or recurrent infection, the consistency of data across the studies published to date makes it clear that tetracycline-related antibiotics are relatively ineffective for the treatment of M. genitalium infections in men.
A single 1-g dose of azithromycin appears to result in significantly higher rates of M. genitalium eradication. Twenty (87%) of 23 azithromycin-treated men in the present study were M. genitalium free at the early initial follow-up visit. Falk et al. [4] followed up 16 men after treatment with the 5-day course of azithromycin and reported that all of them were cured. Björnelius et al. [10] found that the organism was eradicated in 85% of 39 azithromycin-treated men on follow-up. Bradshaw et al. [13] recently reported a somewhat lower success rate (72%) in Australia; of note is that 3 of the patients who experienced treatment failure in that study did not respond to a weekly dose of 1 g of azithromycin taken over 3 weeks. Four M. genitalium isolates from Australian men who experienced initial azithromycin treatment failure were successfully cultivated, and all were resistant to macrolide drugs by in vitro testing. We also documented 2 cases of M. genitalium treatment failure after retreatment with higher-dose azithromycin therapy. In contrast, Björnelius et al. [10] reported a 96% success rate with the 5-day course of azithromycin after failure with tetracyclines. Further study of higher doses of azithromycin is needed to determine the optimal regimen for M. genitalium therapy.
Ours is the only study to date to attempt to see men twice a Clinical status is indicated by whether the patient experienced symptoms or signs of urethral disease (left of virgule; includes complaint of dysuria, urethral itching and/or discharge, and/or urethral discharge on examination) and whether у5 polymorphonuclear leukocytes (PMNLs) per oil-immersion microscopic field were observed in the urethral smear (right of virgule).
after treatment, affording us a unique opportunity to observe the clinical course of persistent M. genitalium infection after treatment for urethritis. There was only 1 bacteriologic and clinical failure at the early follow-up visit. As can be seen in table 2, most patients in both treatment groups were clinically well at the early initial follow-up visit, even though the majority of the doxycycline-treated men were persistently infected. However, 6 of the 14 clinically cured but persistently infected doxycycline-treated men and the single azithromycin-treated man in this category experienced clinical relapse after this visit. This suggests that, even though treatment failure rates were high, the drugs had a suppressive effect on the organism, resulting in a muted host inflammatory response. Alternatively, doxycycline and azithromycin both have anti-inflammatory properties independent of their antibacterial activity, and this may account for the initial improvement in symptoms and signs of infection [14, 15] . From the point of view of the clinician, it should be useful to know that relapsing urethritis may frequently be due to M. genitalium. In fact, Wikström and Jensen [16] recently reported that 41% of those with recurrent or persistent NGU cases in Sweden were M. genitalium positive.
Limitations of the present study include the following. First, although the study was randomized, the clinicians conducting the study were not blinded. However, given that the main outcome measure was persistence or recurrence of M. genitalium infection, this is not likely to have influenced the results, because the laboratory personnel were blinded. Second, the numbers of M. genitalium-infected patients studied were relatively small. However, the difference in treatment outcome was large enough that there is little possibility that a type I statistical error might have occurred. Third, the high lost-to-follow-up rate at the second follow-up visit limited our ability to compare clinical failure between the 2 treatment groups. Therefore, an intent-to-treat analysis was done, which showed a trend toward an increased rate of clinical failure in the doxycycline group, although the difference was not statistically significant. A larger randomized, double-blind study of doxycycline versus azith-romycin that is adequately funded to insure higher compliance and that includes long-term follow-up is needed.
Clearly, bacteriologic treatment failure is significantly more common among men with M. genitalium-positive NGU treated with doxycycline than among those treated with a single dose of azithromycin. However, failure rates of ∼15% or higher also occur after treatment with azithromycin. Moreover, there is evidence that some strains of M. genitalium are resistant in vitro to azithromycin and other macrolide drugs [13] . Patients infected with such strains may experience failure with higherdose and/or more-prolonged azithromycin treatment regimens. The optimal treatment for M. genitalium-associated NGU has not yet been identified, so there is a need for the development and testing of new approaches.
Symptomatic M. genitalium-infected men who experience bacteriologic failure with the initial treatment usually improve clinically immediately after treatment. However, a significant proportion will develop recurrent symptoms within 4 weeks of treatment. Therefore, M. genitalium should be considered a likely cause of recurrent NGU, especially after treatment with doxycycline or other members of the tetracycline class. For such patients, the currently recommended regimen of 2 g of metronidazole and 1 g of azithromycin is appropriate, and most should respond [5] . However, given that 15% of patients with M. genitalium urethritis will experience failure with single-dose azithromycin treatment, a few may have persistent urethritis after receipt of this treatment. An initial dose of 500 mg of azithromycin followed by 250 mg daily for the next 4 days may be effective in some of these cases [10] . Additionally, in an analysis of a small number of patients, Bradshaw et al. [13, 17] reported that 400 mg of moxifloxacin daily for 10 days may be effective for those who experience azithromycin failure. Prospective studies of new approaches to the treatment of recurrent NGU would be useful.
